Testing sarilumab for children with systemic juvenile arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial studies sarilumab, a targeted medicine, to help reduce symptoms in children and teens with systemic juvenile idiopathic arthritis (sJIA) who have not responded enough to current treatments. You may be considered because the study looks at how well and safely repeated doses work in pediatric patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your age is 1 to 17 years (or 6 to 17 if you live in Russia, based on local rules).
- You have a confirmed diagnosis of systemic JIA (sJIA) based on accepted classification rules.
- Your current treatment is not working well enough, and your doctor thinks you may need a “biologic” disease-modifying medicine.
- Your weight fits the study dosing rules (not under 10 kg; not over 60 kg for the initial dose group).
- You have not had recent dangerous flare-ups of sJIA symptoms or macrophage activation syndrome (MAS) in the last 6 months.
- You have no major lung disease like interstitial lung disease, and no certain serious breathing-related lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
This trial tests a new medicine called olokizumab in children and teenagers with juvenile idiopathic arthritis (JIA)—a condition where the immune system causes joint inflammation and pain. The study checks if this drug is safe and effective for children whose arthritis hasn't improved enough with standard treatments.
This study follows children and young adults newly diagnosed with certain types of arthritis or related conditions to learn more about their health over time. It may help doctors better understand how these diseases progress and how treatments work.
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
This trial tests sarilumab, an injected antibody that blocks a key protein involved in inflammation, for people with moderate-to-severe rheumatoid arthritis (RA) who haven't had success with standard treatments. The goal is to see if adding sarilumab can help control joint pain and swelling.
Hear when a new Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.